Evonik Evonik

X

Find the latest Drugs in Development and Pipeline Prospector News of SFA Therapeutics.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
SFA Therapeutics
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
610 Old York Rd, Suite 400, Jenkintown, Pennsylvania 19046
Telephone
Telephone
267-584-1080
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

SFA-002 oral pill acts as down-regulating levels of pro-inflammatory cytokines involved in the pathogenesis of psoriasis including TNF-α, IL-23, IL-12, IL-17 and INF-γ, and down-regulating autoimmunity.


Lead Product(s): SFA-002,Vitamin D,Magnesium

Therapeutic Area: Dermatology Product Name: SFA-002

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 14, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

SFA002 is a new oral therapeutic agent for the treatment of mild-moderate psoriasis. SFA-002 is a potential multi-target and disease-modifying therapeutic that has demonstrated efficacy, safety and durability in Phase 1a studies.


Lead Product(s): SFA-002,Vitamin D,Magnesium

Therapeutic Area: Dermatology Product Name: SFA-002

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 11, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

This 30-subject open-label clinical trial in patients with mild-to-moderate psoriasis will enroll 15 patients into treatment with an initial formulation of SFA002 and an additional 15 subjects into treatment with a second formulation.


Lead Product(s): SFA002

Therapeutic Area: Dermatology Product Name: SFA002

Highest Development Status: IND EnablingProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 29, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

In this important effort to counter the effects of the COVID-19 virus SFA005 is expected to address the cytokine storm linked to Acute Respiratory Distress Syndrome (ARDS) experienced by patients infected with COVID-19.


Lead Product(s): SFA005

Therapeutic Area: Immunology Product Name: SFA005

Highest Development Status: PreclinicalProduct Type: Undisclosed

Recipient: Melior Discovery

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership June 24, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY